BioCentury
ARTICLE | Clinical News

eFT508: Phase I/II started

February 1, 2016 8:00 AM UTC

Effector began an open-label, dose-escalation, dose-expansion, U.S. Phase I/II trial to evaluate oral eFT508 once daily in 21-day cycles in about 120 patients. The company expects data from the dose-e...